Fulcrum director granted options on 32,000 shares

Fulcrum Therapeutics, Inc. director Alan Ezekowitz received a stock option grant covering 32,000 shares of common stock.

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. director Alan Ezekowitz received a stock option grant covering 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036.

According to the terms, the option is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual stockholder meeting after the grant date, as long as service continues. Following this grant, his reported derivative holdings for this option total 32,000 shares.

Insider Trade Summary

Grant/Award: 32,000 shares

Grant/Award 1 txn

Insider Ezekowitz Alan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	32,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 32,000 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Key Figures

Option grant size: 32,000 shares Exercise price: $3.66 per share Expiration date: June 29, 2036 +2 more

5 metrics

Option grant size 32,000 shares Stock Option (right to buy) granted to director

Exercise price $3.66 per share Conversion or exercise price of stock option

Expiration date June 29, 2036 Option expiry for director grant

Shares underlying option 32,000 shares Common Stock underlying derivative security

Post-grant derivative holdings 32,000 shares Total shares following transaction for this option

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 3.6600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"scheduled to vest with respect to all shares on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Fulcrum Therapeutics (FULC) disclose about Alan Ezekowitz in this Form 4?

Fulcrum Therapeutics reported that director Alan Ezekowitz received a stock option grant for 32,000 shares of common stock at an exercise price of $3.66 per share, expiring on June 29, 2036, as part of his director compensation.

How many Fulcrum Therapeutics (FULC) shares are covered by Alan Ezekowitz’s new option?

The new stock option granted to Alan Ezekowitz covers 32,000 shares of Fulcrum Therapeutics common stock. These shares become purchasable upon vesting, giving him the right, but not the obligation, to buy at the fixed exercise price of $3.66 per share.

What is the exercise price of Alan Ezekowitz’s Fulcrum Therapeutics (FULC) stock option?

The exercise price of Alan Ezekowitz’s stock option is $3.66 per share. This means he can purchase up to 32,000 shares of Fulcrum Therapeutics common stock at $3.66, regardless of the market price when he eventually exercises the option.

When does Alan Ezekowitz’s Fulcrum Therapeutics (FULC) option vest and expire?

The option is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or earlier immediately before the first annual stockholder meeting after that date, subject to continued service, and it expires on June 29, 2036.

Is Alan Ezekowitz’s Form 4 transaction in Fulcrum Therapeutics (FULC) a purchase or a grant?

The Form 4 reports a grant of a stock option, not an open-market purchase. It is classified as a “Grant, award, or other acquisition” of a derivative security, giving him the right to buy 32,000 shares of common stock at $3.66.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ezekowitz Alan

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.66	06/30/2026		A		32,000		(1)	06/29/2036	Common Stock	32,000	$0.00	32,000	D

Explanation of Responses:

1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

	/s/ Greg Tourangeau, as attorney-in-fact for Alan Ezekowitz	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)